Pulmonary Hypertension in preterm children born at gestational age <30 weeks: Prevalence, risk factors and outcome.
Completed
- Conditions
- Pulmonale hypertensiePulmonary HypertensionHigh pressure in the lungs1001928010028971
- Registration Number
- NL-OMON44035
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 165
Inclusion Criteria
All premature infants, admitted at the neonatology UMCG, born <30 weeks or birth weight < 1000 gram, who participate in NeolifeS
Exclusion Criteria
no informed consent.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The presence of PH (incidence and prevalence). </p><br>
- Secondary Outcome Measures
Name Time Method <p>Morbidity, Mortality: Quality of life questionnaire and survival.<br /><br><br /><br>Maternal factors: mode of conception, delivery, preterm premature rupture of<br /><br>membranes, maternal disease history, illnesses during gestation, tabacco and<br /><br>medication use.<br /><br><br /><br>Perinatal variables: slow growth patterns in utero, prenatal echo findings,<br /><br>PROM, chorionamniotis, oligoamnion, birth events, placental histology.<br /><br><br /><br>Neonatal variables: development of BPD, low birth weight, gestational age,<br /><br>skull circumference, pulmonary and artficial ventilation variables, oxygen<br /><br>need, presence of PDA, medication, infections, renal function, complications<br /><br>(NEC), slow growth at GA 36wks and at discharge.<br /><br><br /><br>other: demographics, slow growth, admissions, medication, feeding, neurological<br /><br>development, respiratory symptoms, lung clearing index.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pulmonary hypertension development in preterm infants <30 weeks gestation?
What are the comparative outcomes of pulmonary hypertension management strategies in preterm neonates?
Which biomarkers correlate with pulmonary hypertension severity and prognosis in extremely preterm infants?
What adverse events are associated with pulmonary hypertension monitoring in <30 week gestation neonates?
What drug targets are being explored for pulmonary hypertension in preterm infants besides NO donors?